{"DataElement":{"publicId":"3057651","version":"1","preferredName":"Other Retinoic Acid Agent Administered Specify Text","preferredDefinition":"A free-text field to describe another retinoic acid that was administered.","longName":"3040306v1.0:2799057v1.0","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"3040306","version":"1","preferredName":"Other Retinoic Acid Agent Administered","preferredDefinition":"Different than the one(s) previously specified or mentioned._A group of agents that includes retinol (Vitamin A) and related compounds with potential antineoplastic and/or chemopreventive activities.  A retinoic acid agent binds to and/or activates specific nuclear retinoic acid receptors (RARs) and retinoid X receptors (RXRs), thereby modulating transcription of genes responsible for cell differentiation and proliferation.  A retinoic acid agent may exhibit immunomodulatory and anti-inflammatory properties and may inhibit ornithine decarboxylase, resulting in a decrease in polyamine synthesis and keratinization. (NCI04)_The act of having given something (e.g., a medication or test).","longName":"3040309v1.0:2233610v1.0","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"3040309","version":"1","preferredName":"Other Retinoic Acid Agent","preferredDefinition":"Different than the one(s) previously specified or mentioned.:A group of agents that includes retinol (Vitamin A) and related compounds with potential antineoplastic and/or chemopreventive activities.  A retinoic acid agent binds to and/or activates specific nuclear retinoic acid receptors (RARs) and retinoid X receptors (RXRs), thereby modulating transcription of genes responsible for cell differentiation and proliferation.  A retinoic acid agent may exhibit immunomodulatory and anti-inflammatory properties and may inhibit ornithine decarboxylase, resulting in a decrease in polyamine synthesis and keratinization. (NCI04)","longName":"C17649:C804","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Retinoic Acid Agent","conceptCode":"C804","definition":"A group of agents that includes retinol (Vitamin A) and related compounds with potential antineoplastic and/or chemopreventive activities.  A retinoic acid agent binds to and/or activates specific nuclear retinoic acid receptors (RARs) and retinoid X receptors (RXRs), thereby modulating transcription of genes responsible for cell differentiation and proliferation.  A retinoic acid agent may exhibit immunomodulatory and anti-inflammatory properties and may inhibit ornithine decarboxylase, resulting in a decrease in polyamine synthesis and keratinization. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"832CB244-6B85-6B48-E040-BB89AD4314AC","latestVersionIndicator":"Yes","beginDate":"2010-04-01","endDate":null,"createdBy":"LOHNESC","dateCreated":"2010-04-01","modifiedBy":"ONEDATA","dateModified":"2010-04-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2233610","version":"1","preferredName":"Administered","preferredDefinition":"Given.","longName":"C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D864-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"832CB244-6B4E-6B48-E040-BB89AD4314AC","latestVersionIndicator":"Yes","beginDate":"2010-04-01","endDate":null,"createdBy":"LOHNESC","dateCreated":"2010-04-01","modifiedBy":"KUMMEROA","dateModified":"2018-08-15","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2799057","version":"1","preferredName":"Specify Text","preferredDefinition":"Be specific about something; define clearly._Text; the words of something written.","longName":"SPC_TXT","context":"NHLBI","contextVersion":"1","type":"Non-enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2799056","version":"1","preferredName":"Specify Text","preferredDefinition":"Specify; be specific about something; define clearly.:Text; the words of something written.","longName":"C25685:C25704","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Specify","conceptCode":"C25685","definition":"Be specific about something; define clearly.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Text","conceptCode":"C25704","definition":"The words of something written.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B6FE321-D89B-66BC-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-11-11","endDate":null,"createdBy":"NYCHM","dateCreated":"2008-11-11","modifiedBy":"ONEDATA","dateModified":"2008-11-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B6FE321-D8AC-66BC-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-11-11","endDate":null,"createdBy":"NYCHM","dateCreated":"2008-11-11","modifiedBy":"MALUMK","dateModified":"2021-01-19","changeDescription":"03/17/10-Added CSI for F2000-CJL","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2695319","version":"1","longName":"NMDP: CDEs to review","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"2964916","version":"1","longName":"2126r1: Neuroblastoma Post-HSCT Data","context":"NHLBI"}]},{"publicId":"3553940","version":"1","longName":"BRIDG","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"4133055","version":"1","longName":"Version 3.2","context":"NHLBI"}]},{"publicId":"6685474","version":"1","longName":"Artificial Neural Network Algorithm for BRIDG Mapping","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6685476","version":"1","longName":"Training Set","context":"NCIP"}]}],"AlternateNames":[{"name":"neu_post_retinoid_oth_spe","type":"NMDP_FN","context":"NHLBI"},{"name":"MaterialName:name","type":"HCT_BRIDG","context":"NHLBI"}],"ReferenceDocuments":[{"name":"Specify the other retinoids g","type":"Preferred Question Text","description":"Specify the other retinoids given:","url":null,"context":"NHLBI"},{"name":"Specify:","type":"Alternate Question Text","description":"Specify:","url":null,"context":"NHLBI"},{"name":"BRIDG mapping path for CDE:3057651","type":"BRIDG Mapping Path","description":"\"PerformedProcedure > StudyAgent > Product > MaterialName.name WHERE Product.typeCode = \"\"retinoid\"\"   {Post HSCT} is determined by: PerformedProcedure > DefinedProcedure > DefinedCompositeRelationship [1] > DefinedActivity > DefinedCompositeRelationship [2] > DefinedProcedure.nameCode = \"\"Administer Hematopoietic Stem Cell Product {transplantation}\"\" AND DefinedCompositeRelationship.sequenceNumber [1] IS GREATER THAN DefinedCompositeRelationship.sequenceNumber [2]\"","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"840CE794-0273-AE1D-E040-BB89AD433CB1","latestVersionIndicator":"Yes","beginDate":"2010-04-12","endDate":null,"createdBy":"LOHNESC","dateCreated":"2010-04-12","modifiedBy":"KUMMEROA","dateModified":"2021-08-17","changeDescription":"System generated def displayed as alt def.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}